Antibody titers and breakthrough infections with Omicron SARS-CoV-2-Reference-Cited by-同舟云学术

Antibody titers and breakthrough infections with Omicron SARS-CoV-2

Published:2022-04 Issue:4 Volume:84 Page:e13-e15
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Dimeglio Chloé^ORCID,Migueres Marion^ORCID,Mansuy Jean-Michel,Saivin Sylvie,Miedougé Marcel,Chapuy-Regaud Sabine,Izopet Jacques

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference10 articles.

1. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose;Kuhlmann;The Lancet,2022

2. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients;Lu;Clin Infect Dis,2021

3. Antibody titers and protection against a SARS-CoV-2 infection;Dimeglio;J Infect,2021

4. Cross reactivity of spike glycoprotein induced antibody against delta and omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals;Faustini;J Infect,2022

5. Evaluation of three quantitative anti-SARS-CoV-2 antibody immunoassays;Chapuy-Regaud;Microbiol Spectr,2021

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK;PLOS ONE;2024-09-06

2. A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study;Frontiers in Immunology;2023-11-20

3. Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection;Journal of Immunology Research;2023-10-17

4. Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles;Microbiology Spectrum;2023-08-17

5. Protection against Severe Illness versus Immunity—Redefining Vaccine Effectiveness in the Aftermath of COVID-19;Microorganisms;2023-07-31